Currently, the ratio between RANKL and OPG is considered a therapeutic target for treating estrogen deficiency-associated osteoporosis (Rachner et al., 2011), rheumatoid arthritis (Walsh and Gravallese, 2010), Paget’s disease, and bone tumors. Here, TNFRSF11B is linked to Paget disease.